High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations

Rajmohan Murali, M.B.B.S., M.D., F.R.C.P.A., Ben Davidson, M.D., Ph.D., Oluwole Fadare, M.D., Joseph A. Carlson, M.D., Ph.D., Christopher P. Crum, M.D., C. Blake Gilks, M.D., Julie A. Irving, M.D., F.R.C.P.C., Anais Malpica, M.D., Xavier Matias-Guiu, M.D., Ph.D., W. Glenn McCluggage, F.R.C.Path., Khush Mittal, M.D., Esther Oliva, M.D., Vinita Parkash, M.D., Joanne K. L. Rutgers, M.D., Paul N. Staats, M.D., Colin J. R. Stewart, M.D., Carmen Tornos, M.D., and Robert A. Soslow, M.D.

Summary: This review of challenging diagnostic issues concerning high-grade endometrial carcinomas is derived from the authors’ review of the literature followed by discussions at the Endometrial Cancer Workshop sponsored by the International Society of Gynecological Pathologists in 2016. Recommendations presented are evidence-based, insofar as this is possible, given that the levels of evidence are weak or moderate due to small sample sizes and nonuniform diagnostic criteria used in many studies. High-grade endometrioid carcinomas include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated carcinomas, and carcinosarcomas. FIGO grade 3 endometrioid carcinoma is diagnosed when an endometrioid carcinoma exhibits >50% solid architecture (excluding squamous areas), or when an architecturally FIGO grade 2 endometrioid carcinoma exhibits marked cytologic atypia, provided that a glandular variant of serous carcinoma has been excluded. The most useful immunohistochemical studies to make the distinction between these 2 histotypes are p53, p16, DNA mismatch repair proteins, PTEN, and ARID1A.
High-grade endometrial cancers include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated/dedifferentiated carcinomas, and carcinosarcomas. Typical examples of these histotypes are not difficult to diagnose based on careful examination of their morphologic features, allied with confirmatory immunohistochemistry if required. In some cases, the histopathologic and immunohistochemical characteristics are less clear-cut and overlap significantly, which makes accurate classification difficult. Even among specialist gynecologic pathologists, the interobserver reproducibility in the typing of high-grade endometrial carcinomas is suboptimal, with reported kappa values ranging between 0.55 and 0.68 (1–5).

Some studies have shown prognostic differences between the histologic subtypes of high-grade endometrial cancers. In an analysis of 4180 cases by the Surveillance, Epidemiology, and End Results (SEER) Program, poorer outcomes were observed in patients with serous carcinoma and clear cell carcinoma compared with those with grade 3 endometrioid carcinoma (6,7). Other studies found that patients diagnosed with serous carcinoma had poorer survival than those with grade 3 endometrioid carcinoma (8,9). In contrast, 3 studies of high-grade endometrial carcinoma identified no significant differences in survival among patients with grade 3 endometrioid carcinoma, serous carcinoma, and clear cell carcinoma (10–12). Therefore, the issue of whether or not grade 3 endometrioid carcinoma is as clinically aggressive as serous carcinoma and clear cell carcinoma has not been conclusively settled. Much of this controversy is likely due to the suboptimal interobserver reproducibility among pathologists in the histotyping of high-grade endometrial carcinomas.

In this review, we present an overview of the histologic and immunohistochemical features of the different subtypes of high-grade endometrial carcinomas, including a discussion of the challenges in diagnosis and differential diagnosis. We present recommendations based on the available literature to assist pathologists in diagnosing these tumors.

FIGO GRADE 3 ENDOMETRIOID CARCINOMA
Definition
An endometrioid carcinoma with >50% solid architecture, or 6% to 50% solid architecture and diffuse marked nuclear atypia. The presence of oval or round glands, lined by columnar or cuboidal cells with low-grade oval or round nuclei which are typically pseudostratified, establishes endometrioid lineage. Squamous metaplasia (morular or nonmorular) is common and should not be included in the estimation of extent of solid architecture when grading these tumors.

Key Morphologic Features
Grade 3 endometrioid carcinomas frequently arise in association with endometrial hyperplasia. They are predominantly solid (Fig. 1A), but gland formation is usually seen at least focally (Fig. 1B), with evident transition from one component to the other. The solid component consists of large nests and occasional trabeculae. The cells in the solid component resemble those lining the glandular spaces. Nuclei usually have moderate (grade 2) atypia, and mucinous or squamous metaplasia is sometimes seen (13).

ENDOMETRIAL SEROUS CARCINOMA
Definition
An endometrial carcinoma that usually shows marked and diffuse cytologic atypia and a papillary,
FIG. 1. FIGO grade 3 endometrioid carcinoma. Solid architecture (A), glandular architecture with high nuclear grade (B).

FIG. 2. Serous carcinoma. Typical papillary and micropapillary architecture (A), glandular serous carcinoma recognized by highly atypical nuclei and high nuclear:cytoplasmic ratios (B), intraepithelial serous carcinoma involving atrophic endometrial polyp (C).
glandular or solid architecture (Figs. 2A, B). Features definitional for endometrioid carcinoma and clear cell carcinoma (see below) are lacking. Nearly every case harbors a TP53 mutation (14), which is associated with aberrant immunohistochemical expression of p53.

Key Morphologic Features

Serous carcinoma generally develops in the background of atrophic endometrium, sometimes in a polyp (Fig. 2C). Most serous carcinomas show at least focal areas of papillary growth, sometimes with fibrovascular stalks (Fig. 2A); however, this finding may be absent. Budding and exfoliation of tumor cells are typically seen. The tumors may also exhibit irregular glands, often with slit-like spaces, but sometimes with round spaces, or a solid growth pattern (Fig. 2B). Psammoma bodies are found in one-third of cases. Nuclei are hyperchromatic, contain macronucleoli, are markedly atypical (grade 3), and pleomorphic/bizarre forms are often present. Numerous mitotic figures are usually found. Cytoplasm is often scant, but may be more abundant, with a clear or eosinophilic appearance (13,15,16). Some tumors lack marked cytologic atypia, but the tumor cells show hyperchromatic nuclei, increased nuclear:cytoplasmic ratios, numerous apoptotic bodies and frequent mitoses.

Distinction of FIGO Grade 3 Endometrioid Carcinoma and Serous Carcinoma

Morphology

Recognition of key morphologic features detailed above will permit this distinction in most cases. Although serous carcinomas generally show greater degrees of nuclear atypia and polymorphism than grade 3 endometrioid carcinomas, they may both exhibit high-grade atypia and solid growth patterns, and serous carcinomas may show a predominantly glandular growth pattern (13,15,16). Grade 3 endometrioid carcinoma is typically predominantly solid, but glandular or less commonly papillary formation is seen at least focally, with transition from one component to the other (13).

While the aforementioned features aid in distinguishing endometrioid carcinomas and serous carcinomas in many cases, there are some tumors that cannot be reproducibly classified (Fig. 3). In a study of 56 tumors diagnosed as high-grade endometrial carcinomas, 3 experienced gynecologic pathologists agreed on histotype in only 62.5% of cases, and there was disagreement with respect to the diagnosis of grade 3 endometrioid carcinoma versus serous carcinoma in 6 of 20 discrepant cases (2). In view of this difficulty, ancillary methods, such as immunohistochemistry and molecular testing, may be applied aid classification.

Immunohistochemistry

When evaluating immunomarker studies, it is important to bear in mind that reported studies vary in the cut-off points used to assess positive and negative staining, making it difficult to compare the results of different studies.

In a study of 40 grade 3 endometrioid carcinomas and 24 serous carcinomas (17), estrogen receptor (ER), progesterone receptor (PR), p16, monoclonal carcinoembryonic antigen, and vimentin were expressed in 50% versus 54%, 42% versus 54%, 25% versus 92%, 3% versus 13%, and 81% versus 83% of tumors, respectively. This suggests limited discriminatory use for these markers; however, any degree of staining was scored as positive, probably masking the value of diffuse p16 expression in diagnosing serous carcinoma. That the extent of p16 expression might be important was illustrated by a study which found that serous carcinoma showed p16 expression in 90% to 100% of cells, compared with 10% to 90% of cells in grade 3 endometrioid carcinoma (18). Another study (2) using a panel of ER, PR, p16, p53, and PTEN found that the majority of serous carcinomas are negative for ER and PR, positive for PTEN, diffusely positive for p16 and exhibit aberrant mutation-type
expression (diffusely and strongly positive or entirely negative) with p53, whereas grade 3 endometrioid carcinomas are more likely to be positive for ER and PR, negative for PTEN (correlating with genetic aberrations of PTEN(19)), focally positive for p16 and show wild-type staining for p53. However, exceptions to this typical staining pattern occur in both tumor types and in general a panel of markers is the most reliable approach (2).

The insulin-like growth factor II mRNA-binding protein family (IMP; IGFBP) consists of 3 proteins (IMP1, IMP2, and IMP3). IMP2 is expressed in virtually all serous carcinomas and grade 3 endometrioid carcinomas, but in one study, the former showed staining in >95% of tumor cells compared with ≤75% of tumor cells in the latter (20). IMP3 has been shown to be expressed in a majority (>90%) of serous carcinomas (21,22). A panel consisting of IMP3, PTEN, p53, and beta-catenin was applied to 103 endometrial cancers (including 31 serous carcinomas and 16 grade 3 endometrioid carcinomas). IMP3, PTEN, p53, and beta-catenin were detected in 17% versus 100%, 28% versus 90%, 56% versus 84%, and 28% versus 0% of grade 3 endometrioid carcinomas versus serous carcinomas, respectively (23). Another immunohistochemical analysis of 180 endometrial cancers including 34 grade 3 endometrioid carcinomas and 15 serous carcinomas (8) found that IMP3, ER, PR, PTEN, p53, and p16 were detected in 20%, 82%, 68%, 61%, 39%, and 19% of grade 3 endometrioid carcinomas and 63%, 50%, 46%, 100%, 69%, and 90% of serous carcinomas, respectively.

ARID1A is a tumor suppressor gene mutated in ~50% of ovarian endometrioid and clear cell carcinomas, as well as a significant percentage of the corresponding uterine tumors, resulting in loss of immunoeexpression of its protein product, BAF250a. Analysis of 190 high-grade endometrial cancers (24) showed loss of BAF250a expression in 46% of grade 3 endometrioid carcinomas compared with 9% of serous carcinomas. Aberrant p53 expression was found in 18% of grade 3 endometrioid carcinoma compared with 78% of serous carcinomas. In addition, loss of DNA mismatch repair (MMR) protein expression (MLH1, PMS2, MSH2, MSH6) was observed in 57% of grade 3 endometrioid carcinomas compared with 10% of serous carcinomas (24). These patterns of p53 and MMR protein expression have also been reported in other studies (25).

The expression of high-mobility group AT-hook 2 (HMGA2) was compared in 68 grade 3 endometrioid carcinomas and 71 serous carcinomas using tissue microarrays. Staining of any extent was present in 61% of serous carcinomas versus 25% of grade 3 endometrioid carcinomas. When present, staining was more diffuse in serous carcinoma. Serous endometrial intraepithelial carcinomas were also HMGA2-positive (26). In whole tissue sections, 91% of serous carcinomas were positive, usually with diffuse staining. All 5 cases of serous endometrial intraepithelial carcinoma were positive, as were 37% of endometrioid carcinomas, usually with focal staining (26).

WT1 expression is usually focally positive (in up to 30% of cases) or negative in uterine serous carcinoma (27), and this marker is therefore not routinely applied in the differential diagnosis between grade 3 endometrioid carcinoma and serous carcinoma at this anatomic site. However, since endometrioid carcinomas are usually WT1-negative, diffuse WT1 expression when present suggests a diagnosis of serous carcinoma, including derivation from an adnexal serous carcinoma.

In the most comprehensive study of potential markers useful in the distinction between grade 3 endometrioid carcinoma and serous carcinoma published to date, Han et al. (3) analyzed the diagnostic role of 12 proteins (ER, PR, p16, p53, Ki-67, PTEN, beta-catenin, vimentin, IMP3, TFF3, ARID1A, and HNF1B) in this differential diagnosis. TFF3 expression, ARID1A loss and beta-catenin expression had 100% specificity in diagnosing grade 3 endometrioid carcinoma, but relatively low sensitivity at 37%, 33%, and 7%, respectively. p53, p16, and IMP3 stained 94%, 80% and 63% of serous carcinomas, respectively, compared with 26%, 11%, and 11% of grade 3 endometrioid carcinomas (3).

In summary, although individual immunomarkers are differentially expressed in these tumors, no single marker is absolutely diagnostic of either grade 3 endometrioid carcinoma or serous carcinoma. Reaching an accurate, reproducible diagnosis appears to be feasible in most cases using a combination of careful morphologic assessment supplemented by the judicious use of immunohistochemistry with a panel of stains rather than a single marker (Box 1). In general, immunohistochemical markers that can be scored as “all-or-none” or at least as diffuse versus nondiffuse are likely to be assessed in a more reproducible manner than those that require estimation of the extent of staining or staining intensity. The former group includes p16, p53 (Figs. 4A–C), PTEN, DNA MMR proteins (Fig. 4D), and ARID1A (Fig. 4E). ER, despite its expression in a significant number of serous carcinomas, appears to be useful in

Int J Gynecol Pathol Vol. 38, No. 1 Supplement 1, January 2019
Summary and recommendations:
- Carcinomas with a readily identifiable endometrioid component, as evidenced by endometrioid type glands with tall columnar epithelium and stratified nuclei, squamous or mucinous differentiation, and with > 50% solid architecture should be diagnosed as grade 3 endometrioid carcinoma.
- Carcinomas with a solid architecture and a glandular component with serous differentiation (glands with papillae, cellular tufts, high-grade nuclei with macronucleoli, and atypical mitoses) should be diagnosed as serous carcinoma.
- Immunohistochemistry can be a useful adjunct for the distinction between grade 3 endometrioid carcinoma and serous carcinoma. This should be performed in conjunction with careful histologic evaluation, as different subtypes may have significantly overlapping immunohistochemical profiles.
  - A basic panel includes at least p53 and p16 with either ER or PTEN.
  - Double negative [p16-negative (nonblock type)/PTEN-negative* and/or ARID1A-negative or p16-negative/ p53-wild-type] tumors are most likely serous.
  - Double positive tumors (p53 aberrant/mutation-type† and diffuse strong p16 positive)‡ that are also ER-negative§ are more likely serous.
  - Tumors with indeterminate histology and/or discordant immunohistochemistry may be subjected to an expanded immunohistochemical panel that includes DNA MMR proteins (MLH1, PMS2, MSH2, MSH6), beta-catenin, IMP3, and HMGA2.
  - Loss of at least 1 DNA MMR protein by immunohistochemistry may be used to support the diagnosis of endometrioid carcinoma.

*PTEN loss = 0% staining; †p53-aberrant/mutation-type = strong staining in > 80% tumor cells or absent staining; ‡p16 is positive if > 90% strong staining; §ER positive if > 50% staining; ‖DNA MMR protein loss is 0% staining. Controls should be appropriate.

Unresolved questions:
- Is there a role for labeling tumors as indeterminate or ambiguous if histology and immunohistochemistry are insufficiently discriminatory?
- Should molecular genotyping be recommended to distinguish grade 3 endometrioid carcinoma from serous carcinoma or to avoid an indeterminate/ambiguous diagnosis?
- Do the immunohistochemical panels above routinely separate genomically defined variants of grade 3 endometrioid carcinoma, such as those with POLE exonuclease domain hotspot mutations or high copy number alterations?(28)
- How well do these immunomarkers perform in routine clinical practice, given the paucity of rigorous external proficiency testing programs that assess test characteristics?

Combination with these markers, while the evidence for PR is less conclusive. The combination of ER, PR, p16, p53, vimentin, PTEN, and IMP3 was 100% concordant with morphology in the largest study to address this differential diagnosis, with the combination of ER, p16, and p53 being interpreted as the most informative when applying a limited panel of 3 markers (3); however, the role of IMP3 in diagnosing serous carcinoma is more difficult to assess given the different cut-offs applied in different studies. The presence of TFF3 staining, beta-catenin expression and loss of MMR protein expression appears useful in diagnosing grade 3 endometrioid carcinoma and these markers may be included in extended panels.

The role of HMGA2 in this differential diagnosis requires further research. Insufficient evidence is available to support the use of vimentin, Ki-67, HNF1B, WT1 and IMP2, and monoclonal carcinomembrionyic antigen may be safely omitted from the antibody panel. Molecular classification of endometrial carcinomas has been shown to be superior to immunohistochemistry as an ancillary technique (29), but whether, and to what extent, it will replace immunohistochemistry remains to be seen, especially since it is more expensive, more time-consuming and not available in many pathology laboratories.

**CLEAR CELL CARCINOMA**

**Definition**
An endometrial carcinoma demonstrating a combination of papillary (small round papillae lacking overt stratification; Fig. 5A), tubulocystic (Fig. 5B) and/or solid (Fig. 5C) architectural patterns, with cuboidal or polygonal cells containing nuclei with a variable degree of pleomorphism (although usually lacking overt pleomorphism). Hobnail tumor cells and cytoplasmic clearing are often present but are not required for diagnosis.

**Key Morphologic Features**
Clear cell carcinomas of the endometrium are uncommon neoplasms that are likely to be over-diagnosed. Accuracy in the diagnosis of clear cell carcinoma is best achieved by strict adherence to morphologic criteria that are essentially based on the prototypic profile of analogous tumors of the ovary, where clear cell carcinomas are more common and are more reproducibly diagnosed (30–32). The validity of such an extrapolation is supported by the fact that ovarian and endometrial clear cell carcinomas have been shown to have highly similar gene expression, proteomic, morphologic, and immunohistochemical profiles (33–37).

**Architectural Patterns**
Clear cell carcinoma should display at least one of 3 architectural patterns: solid, papillary, and/or tubulocystic. More than 80% of cases show an admixture of 2 or more patterns (34,38). The tubulocystic pattern...
FIG. 4. Immunohistochemistry useful in distinction of serous carcinoma and high-grade endometrioid carcinoma. (A) p53 overexpression (aberrant) may be seen in high-grade endometrioid carcinoma and serous carcinoma. (B) Null p53 phenotype (aberrant) may be seen in high-grade endometrioid carcinoma and serous carcinoma. Note positive internal control. (C) Wild-type p53 expression, not seen in serous carcinoma. (D) Loss of MLH1 expression (aberrant), not seen in serous carcinoma. (E) Geographic loss of ARID1A expression (left), not seen in most serous carcinomas.
is the most commonly encountered, and is at least focally present in most cases (4,34,38), but the papillary pattern is most frequently (28%–41%) predominant (34,38–41).

**Papillary pattern** (Fig. 5A). The papillae of clear cell carcinoma are most commonly in the form of small rounded papillae. Stromal hyalinization is present in the majority of tumors but typically involves only a proportion of the papillae (34). Other papillary patterns include architecturally complex papillae with hierarchical branching, micropapillae, long and slender papillae, or other nonspecific papillary formations (34,40). The papillae of clear cell carcinoma are lined by hobnail, cuboidal, or polygonal cells with clear or eosinophilic cytoplasm, and should not show extensive nuclear stratification, cellular tufting, or detached cellular budding.

**Tubulocystic pattern** (Fig. 5B). The tubulocystic pattern represents a morphologic spectrum from glands/tubules to cystic formations (34,38–43). At the tubular/glandular end of this spectrum, the glands are relatively uniform and display rounded contours with open lumina. They may be extensively confluent and “back-to-back” or show an abundance of interglandular stroma. Increasing cystic dilatation of the glands is usually accompanied by less confluence, although fully cystic units may also be entirely confluent. Tubular glands are lined by polygonal, low cuboidal cells with clear to eosinophilic cytoplasm or by hobnail cells. Cystic glands may be lined by similar cells or by a bland, flat cellular population. The interglandular stroma may be hyalinized, myxoid, inflamed, edematous, or fibroblastic. Extensive nuclear stratification, cellular tufting, or detached cellular budding should not be seen.

*FIG. 5.* Clear cell carcinoma. Papillary architecture (A), tubulocystic architecture (B), solid architecture (C).
**Solid pattern** (Fig. 5C). The solid pattern is almost invariably admixed with other patterns and is characterized by diffuse sheets of polygonal cells with well-defined cell borders, with interspersed thin fibrous septa (34,38–43). Clear cells usually predominate in the solid areas, although a conspicuous population of oxyphilic cells is not infrequent (34).

**Cytologic Features**

**Cell types and stratification.** The cell types that may be seen in clear cell carcinoma include polygonal cells with clear or eosinophilic cytoplasm and well-defined cell membranes, hobnail cells, and attenuated hobnail cells (flat cells) (34,41). Nuclear stratification in the epithelium lining glands and papillae may be focally present and is usually not prominent (34). Cellular tufting or detached cellular budding should not be diffusely present in clear cell carcinoma (34), and squamous differentiation should be absent.

**Atypia.** A given case may display wide variation in the degree of cytologic atypia but many cases show a background of relative monomorphism, with scattered or clustered cells exhibiting larger, pleomorphic nuclei (34). Diffuse severe nuclear atypia is not characteristic of clear cell carcinoma.

**Mitotic index.** The mitotic index may be quite variable between tumors and even within the same tumor, but overall, it is generally low (4,34,41). In one study of 21 cases (41), 52% had 0 to 1 mitotic figures per 10 high power fields, 29% showed 2 to 5 mitotic figures per 10 high-power fields and 19% had ≥ 6 mitotic figures per 10 high-power fields. Putative cases of clear cell carcinoma exhibiting very high levels of mitotic activity, especially when accompanied by severe atypia, warrant careful examination for other characteristic features of clear cell carcinoma.

**Immunohistochemical Features**

The diagnosis of clear cell carcinoma should primarily be based on its distinctive morphologic features described above. However, immunohistochemistry can be useful in some specific scenarios: (1) ascertaining whether focal areas of clear cells in an endometrial carcinoma represent true clear cell carcinoma; and (2) evaluation of a tumor which shows some morphologic features that are suggestive but not diagnostic of clear cell carcinoma in a limited sample (eg, biopsy or curettage).

The typical immunohistochemical profile of clear cell carcinoma is HNF1B-positive (Fig. 6A), Napsin A-positive (Fig. 6B), ER-negative and PR-negative and p53-wild-type (3,4,17,44–55). This immunohistochemical panel is more useful in the distinction of clear cell carcinoma from endometrioid carcinoma than from serous carcinoma. The extent of expression of Napsin A and HNF1B in serous carcinomas and endometrioid carcinomas is significantly lower than that in clear cell carcinomas. HNF1B has high sensitivity for endometrial clear cell carcinoma, but its specificity is lower than in ovarian clear cell carcinoma. Moreover, there are different antibodies against HNF1B, which vary in quality. Use of monoclonal Napsin A is recommended, as the polyclonal antibody lacks specificity (56). A small percentage of prototypical endometrial clear cell carcinomas are ER-positive, and clear cell change in endometrioid carcinoma may be accompanied by significant diminution of ER and PR expression (52); therefore ER and PR should always be used in conjunction with a panel of other markers (57).

Aberrant mutation-type p53 immunohistochemical expression is seen in up to one third of otherwise typical clear cell carcinomas (44,47,58,59) (Fig. 6C) and these cases are morphologically indistinguishable from p53-wild-type cases (47,58). Nevertheless, p53 immunohistochemistry can still provide useful information, as wild-type p53 staining minimizes the probability that the tumor is a true serous carcinoma (5), and mutation-type p53 expression is an adverse prognostic factor in histotypically ambiguous tumors (60). There is some evidence that p53-aberrant clear cell carcinomas show a more aggressive, “serous-like,” peritoneal pattern of spread (58,59). At the molecular level, ~14% of morphologically and immunophenotypically characteristic clear cell carcinomas display a profile of mutations (mutations in TP53 and PPP2R1A; wild-type PTEN, CTNNB1, and ARID1A) typically seen in serous carcinoma (47,48). These findings suggest that a subset of tumors diagnosed as clear cell carcinomas might represent manifestations of extreme morphologic mimicry by serous carcinomas (48,61).

The serous carcinoma-associated markers p16 and IMP3 may be expressed in clear cell carcinoma, and are not particularly useful in the distinction between these 2 tumor types (17,18,21,22,62,63). Although IMP2 and HMGA2 are frequently expressed in serous carcinomas (20,26), there are insufficient data about their expression in clear cell carcinoma. Similarly, the diagnostic value of AMACR (α-methylacyl-coenzyme-A racemase or p504s), which has been reported...
to be frequently positive in clear cell carcinoma, requires further study (64,65). Although loss of DNA MMR protein expression is not useful in the distinction of clear cell carcinoma and endometrioid carcinoma, this finding would favor clear cell carcinoma over serous carcinoma (24,44,66). In 2 recent studies, MMR deficiency was observed in 19% of clear cell carcinomas (67) and 0% of serous carcinomas (68).

**Differential Diagnosis of Clear Cell Carcinoma**

Prototypical examples of endometrial clear cell carcinoma are characterized by a distinctive set of histopathologic features (described above) that enables their distinction from other histotypes (6,7,10,11,34,38–43,69–100). The significant interobserver variation that has historically been associated with the diagnosis of endometrial clear cell carcinoma is in large part related to the propensity for some high-grade (or less commonly low-grade) endometrial carcinomas of other types to contain clear cells and overlap with clear cell carcinoma. In such cases, definitive distinction of clear cell carcinoma from endometrioid carcinoma or serous carcinoma, or a mixed carcinoma with a clear cell component, may be challenging; this is compounded by the relative rarity of endometrial clear cell carcinoma.

**FIG. 6.** Immunohistochemistry in clear cell carcinoma. Hepatocyte nuclear factor 1-beta (HNF1B) is frequently expressed in clear cell carcinoma (A), as is Napsin A (B). A significant minority of endometrial clear cell carcinomas can display aberrant p53 staining (C).

**Distinction of Clear Cell Carcinoma and Endometrioid Carcinoma**

Since clear cell carcinoma is classified and managed as a high-grade carcinoma, it is important...
to distinguish it from low-grade endometrioid carcinoma, with which it may display morphologic overlap (82,90). It is not clear whether the prognosis for patients with clear cell carcinoma differs from that of patients with grade 3 endometrioid carcinoma (or serous carcinoma), with comparably sized bodies of published literature in support of the affirmative (6,7,40,69,70,81,87,88,97) and of the negative (10,11,71,73,80,87,91,94,96). Nevertheless, it is important to distinguish clear cell carcinoma from other histotypes, because: (a) inaccurate histotyping may obscure potentially significant differences between histotypes, including stage distribution, patterns of tumor spread and patterns of recurrence (11,39,89,93); (b) there is some evidence that patients with clear cell carcinoma are at increased risk for venous thromboembolic events (78,85,95); (c) in some institutions, there is a higher likelihood that adjuvant therapy would be recommended for a patient with stage I clear cell carcinoma than for a stage I grade 3 endometrioid carcinoma (101); (d) strict adherence to diagnostic criteria by pathologists will aid study of the molecular profile of clear cell carcinoma (16,102).

Between 12% and 30% of clear cell carcinomas reportedly contain an endometrioid component (38–41,83,89,100). The proportion of these tumors that represent true mixed carcinomas (103) (Fig. 7) rather than a single histotype displaying phenotypic diversity (61) is unclear and the wide range in incidence is likely indicative of interobserver variability in the classification of these tumors (1,4). It is likely that true mixed endometrioid and clear cell carcinoma is very uncommon. Areas of morphologic overlap between clear cell carcinoma and endometrioid carcinoma are largely attributable to the presence of clear cells in endometrioid carcinomas, which may occur for several reasons:

(a) Endometrioid carcinoma with secretory change: secretory change in endometrioid carcinoma is characterized by subnuclear and/or supranuclear vacuoles of glycogen in the epithelial cells of an otherwise typical endometrioid carcinoma (104,105). The cells are columnar (38), compared with the polygonal cells of most clear cell carcinomas. Clear cell carcinomas generally show at least focal higher nuclear grade than endometrioid carcinomas with secretory change (38). These differences are less useful in high-grade endometrioid carcinoma.

(b) Endometrioid carcinoma with clear cell squamous differentiation: squamous differentiation in endometrioid carcinoma may have a variety of appearances, including rounded morules, spindled formations, plaque-like growth, pseudopapillae, micropapillae, and individual keratinized cells (106). All these patterns may display prominent cytoplasmic clearing, usually but not always due to glycogenation, that can mimic clear cell carcinoma (107). Avoiding mischaracterization of squamous differentiation as clear cell carcinoma requires recognition of the morphologic spectrum of squamous differentiation in endometrioid carcinoma, the finding of clear cell areas contiguous with more typical squamous differentiation or endometrioid glands, and the absence of cytoarchitectural patterns of clear cell carcinoma.

(c) Endometrioid carcinoma with nonspecific clear cell change: some endometrioid carcinomas of nonsecretory type exhibit nonspecific clear cell change within the glandular elements (106). Features useful in the distinction from clear cell carcinoma include the absence of the typical architectural patterns of clear cell carcinoma, transitions to typical glandular endometrioid carcinoma and foci of squamous differentiation.

Immunohistochemistry may be of some value in such cases but there can be significant immunophenotypic overlap and markers are often not particularly useful. Negative staining with ER and PR would favor a diagnosis of clear cell carcinoma but these markers can be negative in clear cell areas in endometrioid carcinomas, especially when they exhibit squamous differentiation. While HNF1B and Napsin A are useful markers of clear cell carcinoma,

FIG. 7. Mixed clear cell and endometrioid carcinoma. Note stark difference in cell shape, nuclear features and growth patterns.
they (especially HNF1B) may also be expressed in clear cells in endometrioid carcinomas.

**Distinction of Clear Cell Carcinoma and Serous Carcinoma, and Mixed Clear Cell/Serous Carcinoma**

Although prototypical examples of serous and clear cell carcinoma are readily distinguished, some cases present diagnostic problems (1,2,4). This is due to a number of factors such as the presence of clear cells in some serous carcinomas and serous-like features in some clear cell carcinomas. Current clinical management of patients with serous carcinoma, clear cell carcinoma and mixed serous carcinoma/clear cell carcinoma is not substantially different (101). However, this may change in the future, and accurate diagnosis will facilitate meaningful study of the clinicopathologic and genomic profiles of each histotype. Immunohistochemical markers useful in the distinction between serous and clear cell carcinoma have been discussed previously.

**True Mixed Serous-Clear Cell Carcinomas**

A mixed endometrial carcinoma is defined in the latest World Health Organization (WHO) classification as a carcinoma composed of 2 or more histologic subtypes, in which the minor component constitutes 5% or more of the tumor, and in which the 2 components are recognizable on hematoxylin/eosin-stained sections (103). Each of the components must be spatially distinct from the other(s), and each must exhibit morphologic and immunophenotypic features that, viewed in isolation, is fully diagnostic of one histotype (61). Since evidence from molecular studies suggests that there is a high degree of morphologic mimicry in mixed carcinomas, it is imperative that each component is morphologically and immunophenotypically prototypical (61). As defined, true mixed serous-clear cell endometrial carcinomas are extremely uncommon (Fig. 8A).

**Serous Carcinomas With Cytoplasmic Clearing**

Serous carcinomas that contain cells with clear cytoplasm are much more likely to represent pure serous carcinomas than mixed serous-clear cell carcinomas. The evidence in favor of this interpretation includes: (1) the frequent presence of “clear cells” in endometrial carcinomas of various histotypes minimizes the importance of cytoplasmic clearing as a stand-alone indicator for clear cell carcinoma. (2) Data from ovarian carcinomas, in which histotyping is more reproducible (30–32), indicate that serous carcinomas with clear cells have a morphologic, immunophenotypic and molecular profile that is more consistent with serous carcinoma than clear cell carcinoma (108–110). (3) One seminal study found that in serous carcinomas with clear cells, none of the cases had a tubulocystic pattern, and serous endometrial intraepithelial carcinoma was present in a high proportion of the cases (111).

**Clear Cell Carcinoma With Features that Overlap With Serous Carcinoma (Histologically Ambiguous Carcinomas)**
These are the most challenging tumors to classify. The existence of truly ambiguous tumors in the clear cell carcinoma/serous carcinoma spectrum is one likely contributing factor to the interobserver variability that exists in the histotyping of high-grade endometrial carcinomas (1,2,4). These tumors have hybrid morphologic features overlapping those of serous carcinoma and clear cell carcinoma (Fig. 8B). The frequency of aberrant mutation-type p53 staining in these cases (36%) (112) is comparable with that reported in conventional clear cell carcinoma (33%-38%) (44,47,58,59), and substantially less than that expected in serous carcinoma. Immunohistochemistry, in our experience, has not proven to be very useful in the categorization of this group of cases. The true nature of these cases is unclear, and since they are not prototypical clear cell carcinoma or serous carcinoma, we recommend their provisional categorization in the “ambiguous” category, with descriptive diagnoses such as “High-grade carcinoma with clear cell and serous features” until they can be better categorized by novel modalities in the future. However, such a diagnosis should be made sparingly and only in those cases that defy classification after thorough morphologic and immunohistochemical evaluation.

In summary, otherwise typical serous carcinomas with clear cells should be categorized as serous carcinomas, and serous carcinomas with spatially distinct areas of clear cell carcinoma should be categorized as mixed serous carcinoma-clear cell carcinomas. Cases that are not morphologically typical of either histotype should be reported descriptively (Box 2).

### UNDIFFERENTIATED CARCINOMA AND DEDIFFERENTIATED CARCINOMA

**Definition**

Undifferentiated carcinoma is a solid-pattern tumor lacking overt morphologic evidence of epithelial differentiation, except by immunohistochemistry, where focal (or rarely diffuse) cytokeratin and epithelial membrane antigen (EMA) expression is usually found. Dedifferentiated carcinoma is an undifferentiated carcinoma found in combination with an endometrioid carcinoma that is typically low-grade.

The 2003 WHO classification defined undifferentiated carcinoma simply as lacking any evidence of differentiation (113). However, reproducible recognition of undifferentiated carcinoma was hampered by the lack of a proper operational definition until the 2014 WHO classification (114), in which undifferentiated carcinoma was described as a monomorphic neoplasm which may resemble lymphoma, plasmacytoma, high-grade endometrial stromal sarcoma or small cell carcinoma (115). Undifferentiated carcinoma and dedifferentiated carcinoma of the endometrium should be considered specific entities and these diagnoses should not be used for histologically and/or immuno-
phenotypically ambiguous high-grade tumors that are difficult to classify (116).

Undifferentiated and dedifferentiated carcinomas are clinically aggressive malignancies that are probably under-recognized (115,117,118). They have been widely recognized only in the past decade, and data pertaining to them is based upon a limited number of relatively small studies (115,117–126). In our experience, undifferentiated carcinomas and dedifferentiated carcinomas together represent ∼10% of high-grade endometrial carcinomas and hence about 2% of endometrial carcinomas overall (127). Silva et al. (124) reported that undifferentiated carcinomas accounted for 9% of all endometrial carcinomas; however, this report was from a major tertiary cancer center and it is unclear whether the frequency was inflated due to inclusion of referral and consultation cases.

**Key Morphologic Features**

Undifferentiated carcinoma is a monomorphic neoplasm composed of small to intermediate-sized cells arranged in sheets without any obvious glandular differentiation. They frequently exhibit a characteristic “dyscohesive” pattern and the low-power appearance raises a differential diagnosis of lymphoma, plasmacytoma, high-grade endometrial stromal sarcoma or small cell carcinoma (Fig. 9A) (115,118,121,124).

Approximately 40% of undifferentiated carcinomas are associated with a component of FIGO grade 1 or 2 endometrioid carcinoma; these cases are termed “de-differentiated carcinoma” (Fig. 9B). It is possible that in some cases of undifferentiated carcinoma, an antecedent low-grade component was overgrown by the undifferentiated element. When present, the differentiated low-grade endometrioid component is typically found lining the endometrial cavity, with the undifferentiated component present deep to it. This may account for a diagnosis of low-grade endometrioid carcinoma in a biopsy specimen and dedifferentiated carcinoma at hysterectomy. In rare cases, low-grade endometrioid carcinoma is present in the uterus and the undifferentiated component is only seen in the metastases, which may be identified synchronously or subsequently (117,118,121,124). Rare cases contain foci of FIGO grade 3 endometrioid carcinoma juxtaposed with undifferentiated carcinoma (118).

Additional morphologic features that are present in some undifferentiated and dedifferentiated carcinomas include focal alveolar, nested and vaguelycorded trabecular growth patterns, rhabdoid/plasmacytoid morphology (vesicular nucleus containing a large nucleolus and abundant pink cytoplasm; Fig. 9C), focal marked nuclear pleomorphism (Fig. 9D), multinucleation, spindling, and “abrupt” keratinization (118,124,128,129). Some tumors also show prominent tumor-infiltrating lymphocytes and myxoid stroma. The morphologic criteria have continued to evolve and vary to some extent between studies. For example, the degree of permissible neuroendocrine differentiation (as judged immunohistochemically) was initially restricted to <10% of tumor cells (115), but in one subsequent study of undifferentiated carcinoma, “diffuse staining” was recorded in 9% of cases; we recommend that neuroendocrine marker positivity in undifferentiated carcinoma should be limited to <10% of the tumor cells (129).

**Immunohistochemical Features and Genotype**

The majority of undifferentiated carcinomas (and the undifferentiated component of dedifferentiated carcinoma) lack expression of PAX8, ER, and PR but up to 20% of tumors may show focal staining with these markers (121,130). P53 expression is usually wild-type but is aberrant (mutation-type) in a minority of cases. More than 80% of undifferentiated carcinomas display evidence of epithelial differentiation in the form of intense EMA and cytokeratin (especially cytokeratin 18) staining of a small proportion of tumor cells (Fig. 10A); diffuse expression of EMA and cytokeratins is not typically found but can occur. Tumor cells typically express vimentin and a substantial number express CD138. E-cadherin labeling is absent or minimal (121,130–132). CD34 expression, which is otherwise very uncommon in epithelial neoplasms, is sometimes seen (133). Chromogranin and/or synaptophysin staining can be present, but only in a minority of tumor cells (<10%) (130). Loss of BRG-1 (the protein product of *SMARCA4*) expression can be seen (Fig. 10B), particularly in examples that have DNA MMR protein deficiency and some cases show loss of INI-1 (the protein product of *SMARCBI*) or ARID1A (125,134). BRG-1, INI-1, and ARID1A are involved in chromatin remodeling through SWI/SNF complexes (125,134). Loss of expression of MLH1 and PMS2, mostly due to *hMLH1* promoter methylation is seen in ∼50% to 60% of cases. Rare cases with germline DNA MMR gene mutations diagnostic of Lynch syndrome have been reported (135). Occasional cases may also harbor a hotspot *POLE* mutation affecting the exonuclease domain. Possible mechanisms underlying the transition from differentiated to undifferentiated carcinoma include...
FIG. 9. Undifferentiated and dedifferentiated carcinoma. (A) Prototypical undifferentiated carcinoma. (B) Dedifferentiated carcinoma. (C) Undifferentiated carcinoma containing rhabdoid cells in a myxoid matrix. (D) Undifferentiated carcinoma containing monomorphic and pleomorphic cells. (E) Undifferentiated carcinoma containing multinucleate giant cells. This pattern corresponds to the “giant cell carcinoma” of Scully and is unrelated to other types of undifferentiated carcinomas discussed herein.
the acquisition of mutations in SMARCA4, ARID1B, CTNNB1, PPP2R1A or TP53 (136).

**Differential Diagnosis**

Accurate diagnosis is important in view of the poor prognosis of undifferentiated/dedifferentiated carcinoma, and this is likely to become even more important as tumor subtype-specific targeted therapies are developed.

The differential diagnosis of undifferentiated carcinoma includes grade 3 endometrioid carcinoma, serous carcinoma with a solid architecture, lymphoma, plasmacytoma, melanoma, high-grade endometrial stromal sarcoma, high-grade neuroendocrine carcinoma (small cell and large cell neuroendocrine carcinoma), various metastatic carcinomas, rhabdomyosarcoma, undifferentiated sarcoma and other sarcomas, all of which can be identified with careful morphologic evaluation and the prudent use of immunohistochemical stains. As well as these neoplasms, dedifferentiated carcinoma may be confused with grade 2 endometrioid carcinoma and carcinosarcoma. Many pleomorphic epithelial tumors were likely diagnosed as “undifferentiated carcinoma” before the recognition of the monomorphic tumors currently categorized as undifferentiated carcinomas. Anecdotal experience suggests that many, if not most, pleomorphic carcinomas are merely an extreme end of the spectrum of high-grade endometrial carcinomas, such as serous carcinomas. As with other pleomorphic tumors, the differential diagnosis with melanoma, sarcoma, and hematolymphoid tumors may need to be explored and immunohistochemistry will assist in this distinction.

In contrast to grade 3 endometrioid carcinomas, undifferentiated carcinomas are dyscohesive and do not exhibit epithelial formations, such as glands, although occasional nests and trabeculae are allowed. Undifferentiated carcinoma forms diffuse monotonous sheets, sometimes in a myxoid stroma. Most grade 3 endometrioid carcinomas, on the other hand, are composed of cohesive cells with at least focal glandular formation and squamous differentiation, which may be abortive. While gland formation excludes a diagnosis of undifferentiated carcinoma, the distinction of “true” glands from lacunar-type spaces occurring secondary to apoptosis/necrosis or artifact can be problematic and subjective. The distinction between undifferentiated carcinoma and grade 3 endometrioid carcinoma may be particularly problematic in poorly fixed specimens and sometimes cannot be resolved, even with immunohistochemistry; such cases are probably best diagnosed as “high-grade endometrial carcinoma” with an explanatory note.

Dedifferentiated carcinomas with a significant low-grade glandular component may be misclassified as grade 2 endometrioid carcinoma, significantly underestimating their aggressive behavior (116,124). Dedifferentiated carcinomas may also be confused with grade 3 endometrioid carcinomas but the former is a more overtly “biphasic” neoplasm in view of its distinct low-grade endometrioid and undifferentiated components. However, extensive sampling may be required to identify the differentiated component of dedifferentiated carcinoma. Although by definition

![FIG. 10. Immunohistochemistry in undifferentiated carcinoma of monomorphic type. (A) Focally intense labeling with CK18 in the absence of PAX 8 expression (latter not shown). (B) Loss of BRG-1 (SMARCA4) expression.](Image)
grade 3 endometrioid carcinoma shows a predominant solid growth pattern, up to 49% of the tumor can show glandular differentiation and there is often an intimate admixture of the solid and glandular components within the same nests. The cells within the solid areas and those forming glands usually have similar cytologic appearances. In contrast, the glandular and diffuse elements in dedifferentiated carcinoma are typically separate, and the diffuse component shows greater cytologic atypia than the low-grade glandular component. A solid cohesive growth pattern is characteristic of grade 3 endometrioid carcinomas whereas cellular dyscohesion and rhabdoid morphology are more characteristic of the undifferentiated component of dedifferentiated carcinoma. The distinction between dedifferentiated carcinoma and carcinosarcoma is discussed in the section on carcinosarcoma.

Immunohistochemically, undifferentiated carcinomas and the undifferentiated component of dedifferentiated carcinomas often show loss of PAX8, E-cadherin, ER, and PR immunoreactivity (121,130). In contrast, grade 3 endometrioid carcinomas usually retain PAX8 expression while hormone receptor expression is variable (8). Loss of BRG1 and/or INI1 expression has been reported in undifferentiated carcinoma and the undifferentiated component of dedifferentiated carcinomas (125,134); loss of another subunit of the SWI/SNF complex, BAF250a (the protein product of ARID1A) is common in both low-grade and high-grade endometrial carcinomas (137,138). Overall, therefore a cytokeratin/EMA-focal and PAX8/ER/E-cadherin-negative immunoprofile, along with loss of BRG-1 or INI-1 expression would favor undifferentiated or dedifferentiated carcinoma over grade 3 endometrioid carcinoma (Box 3).

BARCINOSARCOMA

Definition

Carcinosarcoma (formerly termed “malignant mixed Mullerian tumor”) is a biphasic endometrial carcinoma composed of a component of high-grade sarcoma (with or without heterologous elements) juxtaposed with a high-grade carcinoma of the following types: high-grade endometrioid carcinoma, serous carcinoma, clear cell carcinoma, undifferentiated carcinoma, or a histologically ambiguous, high-grade adenocarcinoma. The mesenchymal (sarcomatous) component is presumed to derive from the epithelial component (or concurrent with it from the same progenitor cell) via shifts in differentiation.

BOX 3. Undifferentiated and Dedifferentiated Carcinoma

Summary and recommendations:

- Undifferentiated endometrial carcinoma can be diagnosed when morphologic features of epithelial differentiation are absent.
- Entities in the differential diagnosis should be always be excluded.
- Ideally these carcinomas should be tested for DNA MMR proteins, BRG-1 and INI-1 using immunohistochemistry as a screen. This allows triage for Lynch syndrome and determination of eligibility for clinical trials focused on host immunity and chromatin remodeling.
- The morphologic criteria for undifferentiated carcinoma and dedifferentiated carcinoma continue to evolve, inevitably leading to some variability and subjectivity in diagnosis. In the interim, it may be useful for pathologists to distinguish those cases with classic/prototypical appearances (diffuse/ patternless architecture, monomorphic cytology, dyscohesive appearance, typical immunoprofile), from those cases demonstrating variant features.
- Immunohistochemical studies are essential before making a diagnosis of undifferentiated carcinoma or dedifferentiated carcinoma, particularly to exclude potential histologic mimics. The latter may include non epithelial neoplasms (lymphoma, plasmacytoma, melanoma, sarcoma), metastatic malignancies, and other high-grade endometrial carcinomas such as neuroendocrine carcinomas.
- It is recommended that immunohistochemical expression of neuroendocrine markers in undifferentiated carcinoma be restricted to <10% of tumor cells.
- When the differential diagnosis is with grade 3 endometrial carcinoma, loss of PAX8 and E-cadherin expression and only focal cytokeratin and EMA staining can be useful in supporting a diagnosis of undifferentiated carcinoma or dedifferentiated carcinoma.

Unresolved issues:

- The optimal immunohistochemical panel for distinguishing FIGO grade 3 endometrioid carcinoma and undifferentiated carcinoma is uncertain, but it is likely to include PAX8, pan-cytokeratin, EMA, and E-cadherin.
- The role of molecular analysis in diagnosis at this point is uncertain.

Key Morphologic Features

By definition, carcinosarcoma consists of a high-grade carcinomatous component admixed with malignant mesenchymal elements. There is often a sharp demarcation between the carcinomatous and sarcomatous elements. While immunohistochemistry generally plays a limited role in diagnosis, broad-spectrum cytokeratins may be helpful in problematic cases, by distinguishing between poorly differentiated carcinomatous and sarcomatous elements. Specific skeletal muscle markers (especially myogenin) may be useful in confirming heterologous rhabdomyoblastic differentiation.

The presence of even minimal amounts of carcinomatous epithelium has traditionally been used to
qualify a predominantly sarcomatous tumor as a carcinosarcoma (139). The literature is inconsistent on the volume of sarcomatous differentiation required to label a tumor as a carcinosarcoma, which has ranged from as little as 2% (140) to 25% (141). The authors recommend that the sarcomatous component should measure at least 1 mm in one dimension; while this is an arbitrary figure that is not evidence-based, it reflects the authors’ view that a minimal sarcomatous component should not result in a diagnosis of carcinosarcoma. The clinical significance, if any, of minimal volume sarcoma in a predominantly carcinomatous tumor has not been systematically studied. In contrast, high volume sarcomatous differentiation may portend more aggressive behavior and poor prognosis (139,140,142–144). Some studies also suggest that such largely sarcomatous tumors tend to be associated with pure sarcomatous metastases, which spread preferentially via lymphohematogenous routes to lymph nodes and distant sites, without peritoneal spread (139,140,142,143). This is in contrast to most carcinosarcomas in which the epithelial component preferentially metastasizes to peritoneal sites.

Carcinosarcomas are divided into homologous and heterologous types, according to whether the mesenchymal component exhibits differentiation that is intrinsic (endometrial stromal sarcoma or leiomyosarcoma; Figs. 11A, B) or extrinsic (chondrosarcoma, Fig. 11C; rhabdomyosarcoma, Fig. 11D; etc.) to the uterus. Accurate subclassification of the sarcomatous component is a useful exercise but is not currently relevant to management. This separation was based on reports suggesting a more ominous prognosis for heterologous tumors (145,146) but this remains controversial. One follow-up study concluded that the prognosis for both homologous and heterologous...
carcinosarcomas was equally poor (139). However, a more recent report found significantly poorer 3-yr survival in patients with stage I heterologous tumors (45%) than in those with homologous tumors (93%) (147). The authors concluded that heterologous carcinosarcomas exhibited true sarcomatous differentiation and that homologous tumors were best classified as metaplastic carcinomas based on their behavioral similarity to high-grade endometrial carcinomas.

The morphology of metastases from carcinosarcomas is variable but the majority contain an epithelial component. One study (142) evaluated the cellular composition of 62 metastases, 51 of which were diagnosed at the time of surgery. Carcinoma or carcinosarcoma accounted for over 90% of metastatic tumors, with only a few comprising pure sarcoma. The characteristics of the stromal component, including grade, mitotic index, and the presence and types of heterologous elements, has not been associated with outcome in most studies. In contrast, an epithelial component consisting of serous carcinoma correlates with a higher frequency of metastases. Features associated with poor outcome in carcinomas, such as deep myometrial invasion, lymphovascular space invasion, and cervical involvement, are also associated with adverse prognosis in carcinosarcomas (139,142).

A recent large-scale molecular genetic analysis of uterine carcinosarcomas by the Cancer Genome Atlas (148) revealed extensive copy-number alterations and highly recurrent somatic mutations, most frequently in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS. The similarity in mutational profile to uterine endometrioid and serous carcinomas provides genomic support for the categorization of carcinosarcomas as a subset of uterine carcinomas. A proportion of carcinosarcomas was also characterized by an epithelial-to-mesenchymal transition (EMT) gene signature (148).

In practice, tumors with malignant epithelial and mesenchymal differentiation are reported as carcinosarcomas, with additional comments clarifying the cell type and grade of the epithelial component (although typing of the epithelial component may be particularly difficult in carcinosarcomas), and other parameters that are associated with prognosis in epithelial tumors. The presence of heterologous elements and their differentiation should also be noted.

**Differential Diagnosis of Carcinosarcoma**

A number of neoplasms may enter into the differential diagnosis of carcinosarcoma (Box 4).

### BOX 4. Carcinosarcoma

**Summary and recommendations:**

- The diagnosis of carcinosarcoma requires the presence of sufficient amounts of both carcinomatous and sarcomatous components visible on routinely stained sections to verify a biphasic tumor.

  - **Epithelial component.**
    - The entire spectrum of high-grade epithelial differentiation may be seen in these tumors. However, some patterns appear more strongly associated with carcinosarcoma. These include solid components with marked pleomorphism and variable differentiation, bizarre squamous differentiation and more primitive or “embryonal” glandular growth patterns.

  - **Mesenchymal (sarcomatous) component.**
    - Should be confidently classifiable as sarcoma either histologically or with supportive immunohistochemical stains.
    - Should measure at a minimum 1 mm in one dimension; this is an arbitrary figure, but reflects the authors’ view that a minimal sarcomatous component should not result in a diagnosis of carcinosarcoma.
    - Heterologous mesenchymal differentiation patterns may be seen with pure heterologous sarcomas but are much more likely to signify the presence of a carcinosarcoma.

  - Exclude morphologic mimics of carcinosarcoma before making the diagnosis.
    - Dedifferentiated carcinoma.
    - Adenocarcinoma with prominent desmoplasia (this is excluded by the blandness of the stromal reaction and the lack of nuclear atypia).
    - Solid carcinomas or carcinomas with a spindle cell architecture.
    - Corded and hyalinized endometrioid carcinoma.
    - Carcinomas with benign mesenchymal elements, for example, metaplastic bone.
    - Biphasic carcinomas.
    - Endometrial stromal neoplasm with sex-cord-like differentiation.
    - Adenosarcoma.

**Unresolved questions:**

- What is the minimal amount of carcinomatous epithelium required to designate a predominantly sarcomatous tumor as carcinosarcoma?
- What is the significance of the type and grade of glandular differentiation?

### Dedifferentiated carcinomas and carcinosarcomas

Dedifferentiated carcinomas and carcinosarcomas show a low-power biphasic appearance but in the case of carcinosarcoma, the more diffuse tumor component comprises cytologically malignant mesenchymal elements that are typically spindled and pleomorphic and may exhibit heterologous differentiation (149). This contrasts with the monotonous round cells of the undifferentiated component of most dedifferentiated carcinomas. While dedifferentiated carcinoma can rarely contain a population of somewhat spindled cells, this is usually a minor feature in contrast to the more overtly sarcomatous appearances of carcinosarcoma. Many carcinosarcomas exhibit heterologous...
mesenchymal differentiation, most commonly in the form of chondrosarcoma, rhabdomyosarcoma or osteosarcoma, but this is not a feature of dedifferentiated carcinoma. The epithelial elements of these tumors also differ in that the glandular component of dedifferentiated carcinoma is most often a low-grade endometrioid carcinoma, whereas in most carcinosarcomas, the epithelial element is a high-grade carcinoma (serous, clear cell, grade 3 endometrioid carcinoma or difficult-to-classify high-grade adenocarcinoma). However, the carcinomatous component of a carcinosarcoma can have undifferentiated appearances, at least in some areas, and the distinction from undifferentiated carcinoma or dedifferentiated carcinoma may be very difficult, particularly in biopsy specimens.

Immunohistochemistry has limited utility in this differential diagnosis. Typically, cytokeratins are diffusely expressed by the epithelial component of carcinosarcomas and there is sometimes focal staining of the mesenchymal elements (150). The latter may also express more specific mesenchymal markers if heterologous differentiation is present (eg, myogenin in rhabdomyosarcoma). Vimentin and p16 staining are of limited value since many dedifferentiated carcinomas are positive (130,132). Similarly, PAX8 is not useful in this differential diagnosis since the mesenchymal component of carcinosarcoma, like the undifferentiated component of dedifferentiated carcinoma, is usually PAX8-negative (151). As noted above, loss of MMR protein expression is relatively common (~50%–60% of cases) in dedifferentiated carcinoma (118,125,130), and some tumors arise in patients with Lynch syndrome (152). In contrast, abnormal MMR protein expression is much less common in carcinosarcoma; the Cancer Genome Atlas analysis found microsatellite instability in 2 of 57 (4%) cases (148), although other studies have reported frequencies of MMR-deficient cases ranging between 6% and 33% (153,154).

REFERENCES

1. Fadare O, Parkash V, Dupont WD, et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol 2012;36:1107–18.

2. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37:874–81.

3. Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013;26:1594–604.

4. Han G, Soslow RA, Wethington S, et al. Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1beta. Int J Gynecol Pathol 2015;34:323–33.

5. Hoang LN, McConney MK, Kobel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 2013;37:1421–32.

6. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642–6.

7. Altman AD, Ferguson SE, Ataniefu EG, et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol 2015;139:268–74.

8. Alkushi A, Kobel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343–50.

9. Boruta DM II, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004;101:2214–21.

10. Ayeni TA, Bakkkum-Gamer N, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol 2013;129:478–85.

11. Soslow RA, Bissonnette JP, Walton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007;31:979–87.

12. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol 2012;124:15–20.

13. Soslow RA. High-grade endometrial carcinomas—strategies for typing. Histopathology 2013;62:89–110.

14. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177–85.

15. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004;11:117–42.

16. Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinosarcomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 2011;18:415–37.

17. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenoscarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091–1100.

18. Yemelyanova A, Ji H, Shih-Ie M, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009;33:1504–14.

19. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935–40.

20. Zhang L, Liu Y, Hao S, et al. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol 2011;35:868–72.

21. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008;32:204–13.

22. Li C, Zota V, Woda B, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol 2007;20:1263–8.
23. Mhawech-Fauceglia P, Herrmann FR, Rai H, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2010;133: 899–908.
24. Allo G, Bernardini MQ, Wu RC, et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 2014;27:255–61.
25. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814–24.
26. McCullough WJ, Connolly LE, McBride HA, et al. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology 2012;60:547–53.
27. Barcena C, Oliva E. WT1 expression in the female genital tract. Adv Anat Pathol 2011;18:454–65.
28. Talhouk A, McConney MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.
29. McConney M, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20–30.
30. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1293–51.
31. Kobel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014;64:1004–13.
32. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 2010;34:984–93.
33. DeLair D, Oliva E, Kobel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 2011;35:36–44.
34. Fadare O, Zheng W, Crispens MA, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res 2013;3:70–95.
35. Fata CR, Seeley EH, Desouki MM, et al. Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis. Hum Pathol 2015;46:1427–36.
36. Vang R, Whitaker BP, Farhood Al, et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001;20:252–9.
37. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422–30.
38. Christopherson WM, Alberhasky RC, Connelly PJ, Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982;49:1511–23.
39. Abeler VM, Vergote IB, Kjostad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996;78:1740–7.
40. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995;14:30–38.
41. Kurman RJ, Scully RE. Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer 1976;37:872–82.
42. Kambour-Shakir A, Tobon H. Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol 1991;10:67–78.
43. Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 1987;156:1486–91.
44. Bae HS, Kim H, Young Kwon S, et al. Should endometrial clear cell carcinoma be classified as type II endometrioid carcinoma? Int J Gynecol Pathol 2015;34:74–84.
45. Falade O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol 2014;38:189–96.
46. Falade O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol 2012;20:580–7.
47. Hoang LN, Han G, McConney M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology 2014;64:585–96.
48. Hoang LN, McConkey MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 2015;66:664–74.
49. Holmes BJ, Ronnett BM, Seidman JD, et al. Napsin A: a sensitive immunohistochemical marker for uterine clear cell carcinoma. Mod Pathol 2014;27(suppl 2):536. (Abstract).
50. Iwamoto M, Nakatani Y, Fugo K, et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol 2015;46:957–62.
51. Kim MY, Go H, Koh J, et al. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin. Histopathology 2014;65:195–206.
52. Lim D, Ip PP, Cheung AN, et al. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol 2015;39:1061–9.
53. Mhawech-Fauceglia P, Yan L, Liu S, et al. ER+/PR+/TFF3+/Napsin A+ is frequently expressed in ovarian and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology 2013;62:976–85.
54. O’Keefe M, Longacre TA, Kong CS, et al. Napsin A has utility in the diagnosis of clear cell carcinoma in the ovary but may be less valuable in the endometrium. Mod Pathol 2015;28(suppl 2):530. (Abstract).
55. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007;38:1074–80.
56. Lee S, Piskorz AM, Le Page C, et al. Calibration and optimization of p53, WT1, and Napsin A immunohistochemistry as ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) experience. Int J Gynecol Pathol 2016;35:209–21.
57. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet 1982;4:261–7.
58. Falade O, Gwin K, Desouki MM, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol 2013;26:1101–10.
59. DeLair D, Socloski RA. Endometrial clear cell carcinoma with and without aberrant p53 expression: a study of 16 cases. Mod Pathol 2012;25(suppl 2):265A. (Abstract).
60. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 2010;23:80–92.
61. Kobel M, Meng B, Hoang LN, et al. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am J Surg Pathol 2011;35:156–80.
62. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian-high-grade serous carcinoma. Int J Gynecol Pathol 2007;26:328–33.
63. Fadare O, Liang SX, Crispens MA, et al. Expression of the oncofetal protein IGFBP3 in endometrial clear cell carcinoma: assessment of frequency and significance. *Hum Pathol* 2013;44:1508–15.

64. Fadare O, Parkash V, Gwin K, et al. Utility of alpha-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometroid carcinomas. *Hum Pathol* 2013;44:2814–21.

65. Masand RP, Malpica A, Deavers MT, et al. P504S (AMACR-Alphamethylacyl-co-Racemase): A novel marker of clear cell carcinoma of the female genital tract. Vancouver, BC: Annual Meeting of the United States and Canadian Academy of Pathology; 2012.

66. Arai T, Watanabe J, Kawaguchi M, et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. *Int J Gynecol Cancer* 2006;16:391–5.

67. DeLair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. *J Pathol* 2017;243:230–241.

68. Chen W, Husain A, Nelson GS, et al. Immunohistochemical profiling of endometrial serous carcinoma. *Int J Gynecol Pathol* 2017;36:128–39.

69. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. *Gynecol Oncol* 1991;40:207–17.

70. Abeler VM, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. *Int J Gynecol Cancer* 1992;2:9–22.

71. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometroid FIGO Grade 3 cancer? *Int J Radiat Oncol Biol Phys* 2002;54:79–85.

72. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. *Gynecol Oncol* 1999;74:385–94.

73. Creasman WT, Kohler MF, O’dinico F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage 1 carcinoma of the endometrium. *Gynecol Oncol* 2004;95:593–6.

74. Cuff J, Salari K, Clarke N, et al. Integrative bioinformatics links HNF1β with clear cell carcinoma and tumor-associated thrombosis. *PLoS One* 2013;8:e74562.

75. De Cello A, Rania E, Zuccala V, et al. Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. *Eur J Obstet Gynecol Reprod Biol* 2015;194:153–60.

76. Dobbie BM, Taylor CW, Waterhouse JA. A study of carcinoma of the endometrium. *J Obstet Gynaecol Br Commun* 1965;72:659–73.

77. Eastwood J. Mesonephroid (clear cell) carcinoma of the ovary and endometrium: a comparative prospective clinico-pathological study and review of literature. *Cancer* 1978;41:1911–28.

78. Fadare O, Renshaw IL, Liang SX. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events. *Int J Gynecol Pathol* 2011;30:252–61.

79. Fechner RE. Endometrium with pattern of mesonephroma. Report of a case. *Obstet Gynecol* 1968;31:485–90.

80. Felix AS, Stone RA, Bowser R, et al. Comparison of survival outcomes between patients with malignant mixed Mullerian tumors and high-grade endometrial, clear cell, and papillary serous endometrial cancers. *Int J Gynecol Cancer* 2011;21:877–84.

81. Greggi S, Mangili G, Scaffa C, et al. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. *Int J Gynecol Cancer* 2011;21:661–7.

82. Hasegawa K, Nagao S, Yasuda M, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. *Int J Gynecol Cancer* 2014;24(suppl 3):S90–S95.

83. Hsu KF, Chou HH, Huang CY, et al. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study. *Gynecol Oncol* 2014;134:516–22.

84. Kay S. Clear-cell carcinoma of the endometrium. *Cancer* 1957;10:124–30.

85. Lee L, Garrett L, Lee H, et al. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. *J Reprod Med* 2009;54:133–8.

86. Maggino T, Zola P, Sartori E, et al. Clear cell endometrial cancer: a CTF multicentre Italian study. *Eur J Gynaecol Oncol* 2015;36:428–31.

87. Malpica A, Tornos C, Burke TW, et al. Low-stage clear-cell carcinoma of the endometrium. *Am J Surg Pathol* 1995;19:769–74.

88. Mattes MD, Lee JC, Metzger DJ, et al. The incidence of pelvic and para-aoetric lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. *J Gynecol Oncol* 2015;26:19–24.

89. Murphy KT, Rotmensh J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2003;55:1272–6.

90. Olawaiye AB, Boruta DM II. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. *Gynecol Oncol* 2009;113:277–83.

91. Petignat P, Usel M, Gauthier P, et al. Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. *Eur J Gynaecol Oncol* 2008;29:57–60.

92. Photopulos GJ, Carney CN, Edelman DA, et al. Clear cell carcinoma of the endometrium. *Cancer* 1979;43:1448–56.

93. Randall TC, Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. *J Clin Oncol* 2003;21:4200–6.

94. Rauh-Hain JA, Costauggini I, Olawaiye AB, et al. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. *Eur J Gynaecol Oncol* 2013;34:563–7.

95. Rauh-Hain JA, Hariton E, Clemmer J, et al. Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer. *Obstet Gynecol* 2015;125:1362–70.

96. Reyaers EA, Eenzendam NP, Pijnenborg JM. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer. *J Surg Oncol* 2015;111:790–4.

97. Sakuragi N, Hareyama H, Todo Y, et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. *Acta Obstet Gynecol Scand* 2000;79:311–6.

98. Silverberg SG, De Giorgi LS. Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. *Cancer* 1973;31:1127–40.

99. Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. *Gynecol Oncol* 2008;108:793–7.

100. Varughese J, Hui P, Lu L, et al. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. *J Oncol* 2011;2011:628084.
138. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011;224:328–33.
139. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–19.
140. Macasaet MA, Waxman M, Fruchter RG, et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol 1985;20:32–42.
141. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260–7.
142. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666–74.
143. George E, Manivel JC, Dehner LP, et al. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 1991;22:215–23.
144. Ozguroglu M, Bilici A, Ilvan S, et al. Determining predominating histologic component in malignant mixed mullerian tumors: is it worth it? Int J Gynecol Cancer 2008;18:809–12.
145. Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 1966;28:57–63.
146. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. III. A clinical and pathologic study of 31 carcinosarcomas. Cancer 1966;19:1459–65.
147. Ferguson SE, Tornos C, Hummer A, et al. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653–61.
148. Cherniack AD, Shen H, Walter V, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 2017;31:411–23.
149. Lopez-Garcia MA, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 2010;27:274–86.
150. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321–5.
151. Holmes BJ, Gown AM, Vang R, et al. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma). Int J Gynecol Pathol 2014;33:425–31.
152. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106:87–94.
153. de Jong RA, Nijman HW, Wijbrandi TF, et al. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011;24:1368–79.
154. Hoang LN, Ali RH, Lau S, et al. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. Int J Gynecol Pathol 2014;33:483–91.